Novo hemophila drug approved

Share this article:

The FDA approved Novo Nordisk's Hemophilia A drug Novoeight. The Danish drug maker said in a statement Wednesday that it expects to have the drug on the US market during 2015's second quarter.

The treatment is for a type of hemophilia that typically affects men, and is the result of a missing or malfunctioning factor VIII protein.

The drug was among an elite list of medications approved during the government's 16-day shutdown.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.